The growth and differentiation of normal and malignant breast tissues is regulated by several growth factors. Prolactin (PRL), a known neuroendocrine hormone, is an important growth and differentiation factor for the human breast. We have recently shown widespread expression of PRL and its receptor (PRLr) in malignant and normal breast epithelium. These studies have also demonstrated that treatment of a breast cell line with anti-PRL antibody inhibited its proliferation and survival. these data indicate that breast epithelium utilizes PRL at the autocrine and endocrine level. The autocrine expression of PRL, therefore, may regulate the growth, differentiation, and pathology of the human breast. This hypothesis will be tested in this proposal by three specific aims using normal and malignant human tissues and cells. First, the function of autocrine PRL will be examined in breast tissues and cells in vitro under defined conditions. Second, the functional differences between dimers of PRLr isoforms involved in signal transduction will be investigated through the use of transfected homo- and hetero-dimeric receptor chimeras. Third, PRLr structure will be correlated with function through the in vitro and in vivo use of recombinant PRLr mutants.
These aims will test whether the function and mechanism of action of autocrine PRL and PRLr contribute to the normal and pathologic development of the human breast. The studies proposed here will delineate this autocrine regulatory loop in human breast tissues and characterize the molecular basis for PRL-driven signal at interrupting the autocrine PRL loop in human breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069294-05
Application #
6172830
Study Section
Reproductive Endocrinology Study Section (REN)
Program Officer
Sathyamoorthy, Neeraja
Project Start
1996-04-16
Project End
2002-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
5
Fiscal Year
2000
Total Cost
$247,730
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Zheng, Jiamao; Fang, Feng; Zeng, Xianke et al. (2011) Negative cross talk between NFAT1 and Stat5 signaling in breast cancer. Mol Endocrinol 25:2054-64
Clevenger, Charles V; Gadd, Samantha L; Zheng, Jiamao (2009) New mechanisms for PRLr action in breast cancer. Trends Endocrinol Metab 20:223-9
Clevenger, Charles V; Zheng, Jiamao; Jablonski, Elizabeth M et al. (2008) From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia 13:147-56
McHale, Kevin; Tomaszewski, John E; Puthiyaveettil, Ragunath et al. (2008) Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod Pathol 21:565-71
Zheng, Jiamao; Koblinski, Jennifer E; Dutson, Laura V et al. (2008) Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res 68:7769-78
Swaminathan, Gayathri; Varghese, Bentley; Thangavel, Chellappagounder et al. (2008) Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. J Endocrinol 196:R1-7
Miller, S L; Antico, G; Raghunath, P N et al. (2007) Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene 26:4668-78
Keeler, Camille; Jablonski, Elizabeth M; Albert, Yvonne B et al. (2007) The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry 46:2398-410
Gadd, Samantha L; Clevenger, Charles V (2006) Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol 20:2734-46
Li, Y; Clevenger, C V; Minkovsky, N et al. (2006) Stabilization of prolactin receptor in breast cancer cells. Oncogene 25:1896-902

Showing the most recent 10 out of 29 publications